Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis

Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis: A Randomized, Outcomes-Assessor Masked, Clinical Trial

Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis. Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. The present study is a single-centre, randomized, trial comparing Cliradex® eyelid hygiene and I-Lid 'n Lash® Hygiene, another over-the-counter eyelid wipe, without any medicinal ingredients, in treating chronic blepharitis. The Primary Outcome Measure will be the difference in change in the number of CFU's after 2 weeks treatment, between the groups. The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms by performing a vision check, a questionnaire, and visual grading, of each participants' blepharitis after 2 weeks treatment, between the groups. The Tertiary Outcome Measures will be the difference in change in microbial CFUs and clinical signs and symptoms between the groups at the 4 and 6 week point, (2 and 4 weeks after discontinuing treatment), to evaluate if the treatment will produce a lasting effect.

Participants will be randomized into one of the treatment arms. They will use the appropriate treatment for two weeks. They will then be re-assessed. They will discontinue treatment at this time, and four weeks later, will be assessed one last time, to see if the temporary treatment provides a lasting effect. A sub-group of ten patients per group will also be randomized to an extra visit. This group will be assessed after two weeks of having stopped the wipes. The same testing and procedures will be performed at this appointment.

Study Overview

• Status: Unknown
• Conditions: Meibomian Gland Dysfunction; Blepharitis
• Intervention / Treatment: Other: Tea Tree Oil (TTO); Other: I-Lid'n Lash® Hygiene

Detailed Description

Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis. This randomized, outcomes-assessor masked, clinical trial aims to determine the efficacy of Cliradex®, which contains the most active ingredient of (TTO), as compared with I-Lid 'n Lash® Hygiene, in treating chronic blepharitis

Blepharitis is a family of inflammatory disease processes of the eyelid. It can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis refers to inflammation mainly centered around the eyelashes and follicles, while the posterior variant involves the meibomian gland orifices. Anterior blepharitis usually is subdivided further into staphylococcal and seborrheic variants. Frequently, a considerable overlap exists in these processes in individual patients. Blepharitis often is associated with systemic diseases, such as rosacea and seborrheic dermatitis, as well as ocular diseases, such as dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.1-3

The pathophysiology of blepharitis involves bacterial colonization of the eyelids. This results in direct microbial invasion of tissues, immune system-mediated damage, or damage caused by the production of bacterial toxins, waste products, and enzymes. Colonization of the lid margin is in-creased in the presence of seborrheic dermatitis or meibomian gland dysfunction.1-3

Blepharitis can be difficult to manage because it is often chronic or tends to recur. Despite the cause, eyelid hygiene is the cornerstone of treatment for most cases of blepharitis. This includes the use of commercially available over-the-counter lid cleansing wipes. Previous studies have shown the clinical and microbial efficacy of lid scrubs with tea tree oil (TTO) in resolving chronic blepharitis; however, lid scrubs based on TTO are not convenient for self-administration and cause irritation in some patients.4-11

Cliradex® (Bio-Tissue, Miami, FL) is a commercially available cosmetic pad containing the most active ingredient of TTO, which also exerts potent anti-microbial effects which may eliminate the need for systemic and/or topical antibiotic therapy for blepharitis.

In this trial, the investigators propose to conduct a randomized, outcomes assessor masked, clinical trial to determine the clinical and antimicrobial efficacy of Cliradex® and I-Lid 'n Lash® Hygiene, in improving the signs and symptoms of blepharitis, as well as decreasing the microbial flora in these patients.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1H 8L6
      • Recruiting
      • Ottawa Health Research Institute
      • Contact: Annelise M Saunders, CCRP; Phone Number: 613-737-8657; Email: ansaunders@toh.ca
      • Principal Investigator: Setareh Ziai, MD
      • Sub-Investigator: Yufeng Chen, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with symptomatic blepharitis for duration of at least 3 months.
• Male and female age range: > 18 years old.
• All ethnic groups comparable with the local community.
• Patients able and willing to cooperate with the investigational plan.
• Patients able and willing to complete all postoperative follow-up visits.
• Able to understand and willing to sign a written informed consent.

Exclusion Criteria:

• Patients who are currently engaged in another clinical trial.
• Patients who are unwilling or unable to give consent.
• Patients who are unwilling to accept randomization.
• Patients who will not be able to return for scheduled visits.
• Children under 18.
• Concomitant use of ophthalmic topical medications (excluding non-preserved tear substitutes).
• Concomitant use of systemic antibiotics or steroids.
• Active ocular infection or allergy.
• Previous surgery on the eyelids such as blepharoplasty.
• Abraded skin on or around the eyelids.
• Patients unable to close eyes or uncontrolled blinking.
• Previous allergic reaction to TTO-containing products or cosmetic fragrance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cliradex® eyelid hygiene; Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.	Other: Tea Tree Oil (TTO); Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
Other: I-Lid 'n Lash® Hygiene; Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,	Other: I-Lid'n Lash® Hygiene; Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evidence of microbiologic improvement	difference in change in the number of CFU's after 2 weeks treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as >200)	2 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement in signs & symptoms of blepharitis based on visual grading scale	The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale	2 weeks
Improvement in signs & symptoms of blepharitis based on participant questionnaire	The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire after 2 weeks treatment between the groups.	2 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evidence of continued microbiologic improvement after discontinuing blepharitis treatment	difference in change in the number of CFU's at 2 & 4 weeks post discontinuation of treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as >200)	2 & 4 weeks post discontinuation of treatment
Evidence of continued improvement in signs & symptoms of blepharitis, based on grading scale, after discontinuing blepharitis treatment	The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale	2 & 4 weeks post discontinuation of treatment
Evidence of continued improvement in signs & symptoms of blepharitis, based on participant questionnaire, after discontinuing blepharitis treatment	The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire	2 & 4 weeks post discontinuation of treatment

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Investigators: Principal Investigator: Setareh Ziai, MD, Ottawa Hospital Research Institute

Study record dates

Study Major Dates

• Study Start (Actual): February 19, 2017
• Primary Completion (Anticipated): January 1, 2019
• Study Completion (Anticipated): January 1, 2019

Study Registration Dates

• First Submitted: December 12, 2017
• First Submitted That Met QC Criteria: January 30, 2018
• First Posted (Actual): February 5, 2018

Study Record Updates

• Last Update Posted (Actual): February 5, 2018
• Last Update Submitted That Met QC Criteria: January 30, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Eyelid Diseases; Meibomian Gland Dysfunction; Blepharitis; Anti-Infective Agents, Local; Anti-Infective Agents; Tea Tree Oil
• Other Study ID Numbers: P20130792-01H

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No